Roquefort Therapeutics Past Earnings Performance
Past criteria checks 0/6
Roquefort Therapeutics's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 16.1% annually.
Key information
-8.0%
Earnings growth rate
13.5%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | n/a |
| Return on equity | -31.7% |
| Net Margin | -872.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Roquefort Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -2 | 2 | 1 |
| 30 Sep 23 | 0 | -2 | 2 | 1 |
| 30 Jun 23 | 0 | -2 | 2 | 1 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 0 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
Quality Earnings: ROQ is currently unprofitable.
Growing Profit Margin: ROQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ROQ's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ROQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ROQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: ROQ has a negative Return on Equity (-31.72%), as it is currently unprofitable.